Drug Search Results
More Filters [+]

Tigapotide

Alternative Names: tigapotide, pck-3145, pck3145, pck 3145
Latest Update: 2009-03-30
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Angiogenesis Inhibitor,Apoptosis Stimulant

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sloan Kettering Medical Center
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tigapotide

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Prostate Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT00695851

P1

Completed

Prostate Cancer

2009-03-01

Recent News Events

Date

Type

Title